Positive PREPS Study Outcome

RNS Number:6060O
Henderson Morley PLC
25 February 2008

                                                                25 FEBRUARY 2008

                              HENDERSON MORLEY PLC
                                     (AIM)

                        Business: Drug Discovery Company

                          POSITIVE PREPS STUDY OUTCOME



The Board of Henderson Morley plc, the AIM listed vaccine and anti-viral drug
development company, is pleased to announce the completion of studies regarding
its PREPS and L-particles vaccine platform.

The studies were undertaken by a US-based contract research organisation, and
examined safety, antigenicity and immunogenicity of PREPS and L-particles in
laboratory models.



HIGHLIGHTS

  * PREPS and L-particles demonstrated to be stable, safe, and well tolerated.

  * These positive results will now lead to further studies.

  * These technologies are being developed to target a number of important
    diseases.



PREPS and L-particles were demonstrated to be stable, safe, and well tolerated.
The studies also demonstrated that a potent and dose related immune response was
generated to the target antigen. These positive results will now lead to further
studies examining engineered PREPS and L-particles targeted at either cancer or
other model antigens.

These studies will aide the further development of PREPS and L-particles as
cancer immunotherapeutic candidates. The studies will also aide with
identification and selection of lead candidate vaccines.

These technologies are being developed to target a number of important diseases
including virus infections in humans such as Cytomegalovirus, Epstein Barr virus
and herpes simplex virus, and as a cancer immunotherapy for a wide range of
different forms of human and animal cancers.

Executive Chairman Andrew Knight said: "We are delighted with the initial
positive outcome of these studies. We are working on an important vaccine
programme and look forward to further developing our technologies to target a
wide range of diseases. "


                                   ---ENDS---



Enquiries:

HENDERSON MORLEY PLC                                         Tel: 0121 442 4600
Andrew Knight, Chairman

BISHOPSGATE COMMUNICATIONS LTD                               Tel: 020 7562 3350
Maxine Barnes
Nick Rome

BREWIN DOLPHIN LTD                                           Tel: 0113 241 0126
Neil Baldwin



Notes for editors

Antigenicity and immunogenicity- ability of vaccine to develop an immune
response



PREPS and L-particles

This vaccine platform has a wide range of potential applications including, but
not limited to:

     Infectious disease-  HSV, CMV, EBV,
     Cancer- immunotherapeutic against a wide range of antigens
     DNA vaccines- as a biological adjuvant


This vaccine platform has a number of distinct advantages over existing
technologies:

     Virus like particles that contain full complement of virus proteins
     Non replicating and contain no DNA
     Wide range of proteins may be expressed






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

STRPUURCPUPRGQP

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024